학술논문
Hepatitis-B virus infection in India: Findings from a nationally representative serosurvey, 2017-18.
Document Type
Academic Journal
Author
Murhekar MV; Indian Council of Medical Research (ICMR)-National Institute of Epidemiology, Chennai, India. Electronic address: mmurhekar@nieicmr.org.in.; Santhosh Kumar M; Indian Council of Medical Research (ICMR)-National Institute of Epidemiology, Chennai, India.; Kamaraj P; Indian Council of Medical Research (ICMR)-National Institute of Epidemiology, Chennai, India.; Khan SA; ICMR-Regional Medical Research Centre, Northeast Region, Dibrugarh, India.; Allam RR; Science Health Allied Research Education India, Hyderabad, India.; Barde P; ICMR-National Institute of Research in Tribal Health, Jabalpur, India.; Dwibedi B; ICMR-Regional Medical Research Centre, Bhubaneswar, India.; Kanungo S; ICMR-National Institute of Cholera and Enteric Diseases, Kolkata, India.; Mohan U; King George's Medical University, Lucknow, India.; Mohanty SS; ICMR-Desert Medicine Research Centre, Jodhpur, India.; Roy S; ICMR-National Institute of Traditional Medicine, Belagavi, India.; Sagar V; Postgraduate Institute of Medical Education and Research, Chandigarh, India.; Savargaonkar D; ICMR-National Institute of Malaria Research, New Delhi, India.; Tandale BV; ICMR-National Institute of Virology, Pune, India.; Topno RK; ICMR-Rajendra Memorial Research Institute of Medical Sciences, Patna, India.; Girish Kumar CP; Indian Council of Medical Research (ICMR)-National Institute of Epidemiology, Chennai, India.; Sabarinathan R; Indian Council of Medical Research (ICMR)-National Institute of Epidemiology, Chennai, India.; Bitragunta S; Indian Council of Medical Research (ICMR)-National Institute of Epidemiology, Chennai, India.; Grover GS; Department of Health and Family Welfare, Government of Punjab, Punjab, India.; Lakshmi PVM; Postgraduate Institute of Medical Education and Research, Chandigarh, India.; Mishra CM; King George's Medical University, Lucknow, India.; Sadhukhan P; ICMR-National Institute of Cholera and Enteric Diseases, Kolkata, India.; Sahoo PK; ICMR-Regional Medical Research Centre, Bhubaneswar, India.; Singh SK; King George's Medical University, Lucknow, India.; Yadav CP; ICMR-National Institute of Malaria Research, New Delhi, India.; Kumar R; Postgraduate Institute of Medical Education and Research, Chandigarh, India.; Dutta S; ICMR-National Institute of Cholera and Enteric Diseases, Kolkata, India.; Toteja GS; ICMR-Desert Medicine Research Centre, Jodhpur, India.; Gupta N; Epidemiology and Communicable Diseases Division, ICMR, New Delhi, India.; Mehendale SM; Epidemiology and Communicable Diseases Division, ICMR, New Delhi, India.
Source
Publisher: Elsevier Country of Publication: Canada NLM ID: 9610933 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3511 (Electronic) Linking ISSN: 12019712 NLM ISO Abbreviation: Int J Infect Dis Subsets: MEDLINE
Subject
Language
English
Abstract
Introduction: India introduced a hepatitis-B (HB) vaccine in the Universal Immunization Program in 2002-2003 on a pilot basis, expanded to ten states in 2007-2008 (phase-1), and the entire country in 2011-2012 (phase-2). We tested sera from a nationally representative serosurvey conducted duing 2017, to estimate the seroprevalence of different markers of HB infection among children aged 5-17 years in India and to assess the impact of vaccination.
Methods: We tested sera from 8273 children for different markers of HB infection and estimated weighted age-group specific seroprevalence of children who were chronically infected (HBsAg and anti-HBc positive), and immune due to past infection (anti-HBc positive and HBsAg negative), and having serological evidence of HB vaccination (only anti-HBs positive). We compared the prevalence of serological markers among children born before (aged 11-17 years) and after (aged 5-10 years) introduction of HB-vaccine from phase-1 states.
Results: Among children aged 5-8 years, 1.1% were chronic carriers, 5.3% immune due to past infection, and 23.2% vaccinated. The corresponding proportions among children aged 9-17 years were 1.1%, 8.0%, and 12.0%, respectively. In phase-1 states, children aged 5-10 years had a significantly lower prevalence of anti-HBc (4.9% vs. 7.6%, p<0.001) and higher prevalence of anti-HBs (37.7% vs. 14.7%, p<0.001) compared to children aged 11-17 years. HBsAg positivity, however, was not different in the two age groups.
Conclusions: Children born after the introduction of HB vaccination had a lower prevalence of past HBV infection and a higher prevalence of anti-HBs. The findings of our study could be considered as an interim assessment of the impact of the hepatitis B vaccine introduction in India.
(Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Methods: We tested sera from 8273 children for different markers of HB infection and estimated weighted age-group specific seroprevalence of children who were chronically infected (HBsAg and anti-HBc positive), and immune due to past infection (anti-HBc positive and HBsAg negative), and having serological evidence of HB vaccination (only anti-HBs positive). We compared the prevalence of serological markers among children born before (aged 11-17 years) and after (aged 5-10 years) introduction of HB-vaccine from phase-1 states.
Results: Among children aged 5-8 years, 1.1% were chronic carriers, 5.3% immune due to past infection, and 23.2% vaccinated. The corresponding proportions among children aged 9-17 years were 1.1%, 8.0%, and 12.0%, respectively. In phase-1 states, children aged 5-10 years had a significantly lower prevalence of anti-HBc (4.9% vs. 7.6%, p<0.001) and higher prevalence of anti-HBs (37.7% vs. 14.7%, p<0.001) compared to children aged 11-17 years. HBsAg positivity, however, was not different in the two age groups.
Conclusions: Children born after the introduction of HB vaccination had a lower prevalence of past HBV infection and a higher prevalence of anti-HBs. The findings of our study could be considered as an interim assessment of the impact of the hepatitis B vaccine introduction in India.
(Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)